Breaking through in a crowded oncology market is hard enough—doing it across multiple indications, over multiple years, with a lean team and a brand-new company story to tell at the same time is a different challenge entirely. Lumanity’s strategy-led AOR model gave this emerging biopharma a rare combination: the strategic horsepower to sharpen differentiation and build a durable core narrative, fused with the execution engine to deliver high-quality medical communications consistently across every data readout and launch wave. The outcome was a company and asset story that held together under competitive pressure and earned genuine credibility with external experts.

When an emerging biopharma company faced its first global launch with lean internal capabilities and high-stakes decisions at every turn, they needed an integrated partner who could move at launch speed. Lumanity embedded a senior-led, cross-functional team to unify strategy, evidence, access, and engagement under a single operating cadence, using our Ignite platform to keep decisions moving and workstreams aligned. The result was a launch-ready roadmap anchored in a compelling, patient-centered value story—backed by the governance model and payer-ready evidence to give external stakeholders the confidence to act.

When a leading pharmaceutical manufacturer faced unprecedented Medicare drug price negotiations under the Inflation Reduction Act, they turned to Lumanity’s unmatched blend of strategy, evidence, engagement, and technology. Mobilizing over 40 experts across market access, pricing, and HEOR, Lumanity crafted a first-of-its-kind submission strategy—securing a higher Maximum Fair Price than the competition. This landmark success not only safeguarded their blockbuster drug’s value, but also solidified an ongoing strategic partnership.

When the world’s largest pharmaceutical distributor set out to build a competitive Cell and Gene Therapy business—entering the market later than its rivals—speed, differentiation, and precision were non‑negotiable. Partnering with Lumanity, they combined deep CGT market insights with bold creative branding to launch a customer‑tailored go‑to‑market strategy that stands out in a fast‑moving, high‑stakes industry. The result? A business poised not just to compete, but to lead in the next era of advanced therapies.